Body composition as predictor of toxicity and outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) receiving nivolumab (Nivo).

e21010Background: Low muscle mass is associated with adverse cancer outcomes including increased chemotherapy toxicity and reduced survival, while adiposity is linked to chronic low grade inflammat...